Subtype
Urinary System Adenocarcinoma
CI-CAN-00004181Explore in graph →
378 active trials17 approved drugs60 evidence items
- NCIt
- C224634
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00004181Explore in graph →
Clinical trials
1,629 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (279)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03821376 | Correlation of Renal Mass Pathologic Grade and Contrast Enhanced Ultrasound (CEUS) | terminated | Phase 4 | 12 | Indiana UniversityOTHER | 1 | Oct 10, 2024 | clinicaltrials |
| NCT02338570 | Outcome-related Factors in Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus (ORCHIDEE)(ORCHIDEE) | terminated | Phase 4 | 31 | Mario Negri Institute for Pharmacological ResearchOTHER | 1 | Feb 5, 2018 |
| clinicaltrials |
| NCT00930345 | Biological, Pathological and Imagery Markers in the First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma(PREINSUT) | terminated | Phase 4 | 33 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Apr 1, 2015 | clinicaltrials |
| NCT00352859 | Phase IV Randomization to On-Going Treatment to Evaluate Sustained Sorafenib | terminated | Phase 4 | 2 | BayerINDUSTRY | 1 | Dec 30, 2014 | clinicaltrials |
Data updated 22 days agoSource updated Oct 10, 2024source: clinicaltrials